Same Quality, Lower Cost: the vendor switch playbook
Most teams treat their vendor list as fixed. Graphtal's 12-material assessment across 6 categories found roughly 26% of material spend sitting in plain sight.
Most biosimilar manufacturing teams treat their vendor list as fixed benchmark pricing from a handful of established, well-known suppliers across resin, media, and filtration. It's the safe, well-worn path. It's also, according to Graphtal's alternative vendor cost assessment, leaving roughly 26% of material spend on the table.
Cost figures in this analysis are illustrative and directional always verify against current vendor quotes before acting on any specific number.
For each material, we compared the current vendor's cost per unit against two independently sourced alternative candidates, averaged their pricing, and calculated the per-batch and annualized savings.
Percentage savings and dollar savings don't always point to the same material and that distinction matters when prioritizing validation effort.
The single biggest opportunity on the list feed supplements isn't glamorous, but at $47,500 saved per batch, it dwarfs almost everything else once multiplied across ~26 batches a year.
| Material | Current Cost | Alt Vendor (avg) | Savings % |
|---|---|---|---|
| Virus Pre-filter (10") | $4,275 | $575 | 87% |
| Media Filter (5") | $678 | $100 | 85% |
| SU Bioreactor Bags (2000L) | $18,000 | $3,300 | 82% |
| Media Filter (10") | $839 | $150 | 82% |
| Media Filter (30") | $2,519 | $500 | 80% |
| TFF/UF-DF Membrane (30kDa) | $17,000 | $5,500 | 68% |
Filtration consumables show the steepest percentage cuts across the board incumbent vendors carry a premium on validated single-use filter housings that qualified alternative suppliers can undercut by 4–5x on unit cost.
Protein A resin shows a 46% cost reduction potential but the per-batch dollar impact looks modest because resin is reused across many cycles, not purchased fresh each run.
The real opportunity with resin isn't the per-batch number; it's multi-year total cost of ownership once cycle life and dynamic binding capacity (DBC) are validated expect a 100–150+ cycle life study before committing. CEX and AEX polishing resins, by contrast, showed only modest or slightly negative savings once cycle-life and column-volume assumptions were applied a reminder that percentage headlines can mislead without checking the underlying batch economics.
That 26.4% isn't a single vendor negotiation it's the sum of dozens of smaller, individually low-risk swaps: cheaper filter housings here, a better-priced feed supplement there, a validated alternative resin candidate in the wings. None of them alone would justify a strategy meeting. Together, they're a meaningful line item on the P&L.
Every candidate in the assessment carries a documented next step this isn't a "switch everything tomorrow" list.
Validation timelines for critical materials typically run 6–18 months depending on how close the material sits to product-contact and viral clearance claims exactly why this kind of assessment needs to happen well ahead of your next tech transfer or facility fit exercise.
Vendor cost work is only useful if the basis is transparent. Here's what underlies every figure above.
| Assumption | Value Used |
|---|---|
| Production scale basis | 400 kg DS/year |
| Annual usage volumes | Based on 2,000 L Fed-Batch process; scaled linearly with output |
| Batch reference | Same Fed-Batch batch economics used in the Process Comparison model |
| Cost data source | Illustrative directional only; verify against current vendor quotes before implementation |
| Validation timelines | 6–18 months depending on material criticality (product-contact vs. non-contact) |
| Alt vendor pricing | Averaged across two independently sourced alternative candidates per material |
| Resin savings basis | Per-batch impact only excludes multi-year cycle-life and DBC value not yet validated |
| Editable inputs | All cost values in blue text in the source workbook are user-editable inputs |
All figures are hypothetical and built for illustrative, strategic modelling purposes only internal Graphtal Analytics framework. Verify all vendor pricing directly before committing to any material switch.
This kind of material-by-material teardown isn't a one-off exercise for us it's part of how Graphtal supports biopharma, CDMO, and cell therapy teams end-to-end.
Tell Us About Your Project
Our team of experienced professionals at Graphtal is ready to transform your project from idea to reality, ensuring alignment with your organisation goals through advanced data analytics and predictive modelling.
Let's simplify your work